Mylan rewarded for 'tens of millions' spend on Copaxone generic

4 October 2017
drugs_pills_tablets_big

Market activity on Wednesday underlined the importance of a US Food and Drug Administration (FDA) approval of a generic drug from Mylan (Nasdaq: MYL).

The Netherlands-incorporated drugmaker won approval for its generic version of Copaxone (glatiramer acetate) at 40mg/mL for a three-times-a-week injection, and the once-daily 20mg/mL injection.

Copaxone is indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS) and is marketed by Israel’s Teva Pharmaceutical Industries (NYSE: TEVA), which has waged a  long legal battle against Mylan in its attempts to hang onto exclusivity.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics